|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral route
|
|
gptkbp:approves
|
gptkb:2010
gptkb:FDA
|
|
gptkbp:atccode
|
N07 XX02
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:available_in
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:bioavailability
|
approximately 95%
|
|
gptkbp:brand
|
gptkb:Ampyra
|
|
gptkbp:casnumber
|
86200-24-6
|
|
gptkbp:class
|
neurological agent
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
positive outcomes reported
MS walking improvement study
|
|
gptkbp:clinical_use
|
symptomatic treatment
improving walking in MS patients
|
|
gptkbp:contraindication
|
seizures
seizure history
|
|
gptkbp:development
|
gptkb:Acorda_Therapeutics
|
|
gptkbp:dosage_form
|
extended-release tablet
|
|
gptkbp:drug_interactions
|
caution with other CNS stimulants
|
|
gptkbp:duration
|
ongoing
as prescribed by physician
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:fdalabel
|
contains warnings and precautions
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:formulation
|
oral tablet
|
|
gptkbp:funding
|
gptkb:NIH
|
|
gptkbp:healthcare
|
January 2010
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ampyra
|
|
gptkbp:indication
|
improving walking in MS patients
|
|
gptkbp:ingredients
|
dalfampridine
|
|
gptkbp:invention
|
2027
|
|
gptkbp:is_effective_against
|
improves walking speed
|
|
gptkbp:is_monitored_by
|
required for seizure history
|
|
gptkbp:label
|
prescription only
|
|
gptkbp:lifespan
|
5 to 6 hours
|
|
gptkbp:manufacturer
|
gptkb:Acorda_Therapeutics
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:market_launch
|
gptkb:2010
|
|
gptkbp:marketed_as
|
gptkb:Acorda_Therapeutics
gptkb:Ampyra
|
|
gptkbp:mechanism_of_action
|
potassium channel blocker
|
|
gptkbp:metabolism
|
not extensively metabolized
minimal hepatic metabolism
|
|
gptkbp:monitors
|
0 D1 B1 B1 D1 B
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_education
|
important for understanding use
|
|
gptkbp:patient_population
|
adults
adults with MS
|
|
gptkbp:pharmaceutical_company
|
gptkb:Acorda_Therapeutics
|
|
gptkbp:pharmacokinetics
|
renal excretion
well absorbed
enhances nerve conduction
|
|
gptkbp:previous_name
|
dalfampridine
|
|
gptkbp:price
|
high
approximately $1,000 per month
|
|
gptkbp:provides_guidance_on
|
recommended for MS treatment
|
|
gptkbp:requires
|
available online
available
|
|
gptkbp:research
|
ongoing for long-term effects
|
|
gptkbp:research_focus
|
improving mobility in MS patients
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
Category C
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
anxiety
dizziness
fatigue
headache
nausea
seizures
insomnia
tremors
urinary tract infection
visual disturbances
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:structure
|
C10 H12 N4 O2
|
|
gptkbp:support
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:trade
|
gptkb:Ampyra
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
gptkb:multiple_sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Acorda_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|